Orthocell Ltd · ASX:OCC
Orthocell — Q1 FY27 Earnings Presentation
23 slides from Orthocell's earnings presentation, Oct 22, 2026
Slide 1: Q1 FY27 Investor Webinar
rsonal use only Q1 FY27 Investor Webinar Thursday 22nd October 2026
Slide 2: Disclaimer
Disclaimer rsonal use only This presentation, prepared by Orthocell Ltd (“Company”), does not constitute, representations contained in this presentation, and they do not accept any liability or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy whatsoever (includi
Slide 3: Orthocell at a Glance
Orthocell at a Glance Australian medical technology company with growing international revenue driven by the commercialisation of its flagship nerve repair product, Remplir , in the ~US$2 billion U.S. market1. rsonal use only Fully funded and Remplir U.S. strategy US$3.5 billion1 global investing in
Slide 4: The Lassonde Curve | Market Valuation Lifecycle
The Lassonde Curve | Market Valuation Lifecycle 18 months post-FDA clearance, OCC is entering the inflection point of its US growth curve — with the commercial platform established and FY27 revenue growth ahead. rsonal use only 3 Breakeven1 Penetration of the ~US$2bn U.S. nerve repair market HIGH 2
Slide 5: Key highlights for the quarter ended September 2026
Key highlights for the quarter ended 30 September 2026 U.S. commercial foundations established: Remplir unit sales increasing 25% QoQ, U.S. growth is reaching its inflection point, and initial clinical results indicating early return to urinary control following nerve-sparing prostatectomy. rsonal u
Slide 6: Key performance metrics
Key performance metrics Strong Remplir momentum continued in the September quarter, with global sales increasing 20% quarter-on- quarter and U.S. unit sales rising 25% to 149. Lower non-Remplir revenue impacted total quarterly revenue; however, rsonal use only this is expected to recover in the comi
Slide 7: Quarterly revenue
Quarterly revenue U.S. Remplir revenue grew 21% quarter-on-quarter. While non-Remplir revenue was lower in the September quarter, it is expected to recover in the coming quarters. rsonal use only Total Revenue1 by Quarter (A$M) U.S. Remplir Revenue by Quarter (A$M) 19% 0.40 YoY 3.8 3.6 0.33 3.2 0.30
Slide 8: Remplir Prostatectomy Case Series
Remplir Prostatectomy Case Series Adoption in Australian prostatectomy procedures is gathering momentum, with more than 300 procedures now completed and multiple surgeons routinely using the product. rsonal use only Initial Remplir prostatectomy case series shows excellent early functional recovery
Slide 9: Cash Flow
rsonal use only Cash Flow Jim Piper Chief Financial Officer
Slide 10: Quarterly cash flow summary
Quarterly cash flow summary Sustainable cash reserves are in place to fund the commercialisation of Remplir and support the business to profitability, with no additional funding anticipated. rsonal use only AUD $M 2Q FY26 3Q FY26 4Q FY26 1Q FY27 Receipts from customers 1.2 1.6 2.5 2.6 • $39.0 millio
Slide 11: U.S. Remplir
rsonal use only U.S. Remplir Adam Wood Chief Commercial Officer
Slide 12: Remplir significant US$2 billion U.S. market opportunity
1 Remplir significant US$2 billion U.S. market opportunity We are targeting 10% of the 700,000 annual U.S. Peripheral nerve repair procedures, with Orthocell cash breakeven at ~6,000 procedures. rsonal use only Targeting 10%, with a focus on the short-gap Breakeven2 700,000 and non-transected nerve
Slide 13: The Four Major U.S. States Are Now Covered
The Four Major U.S. States Are Now Covered With a combined population of ~114m, Orthocell has established coverage across four strategically important U.S. markets, providing a strong platform for future growth. rsonal use only Florida Recent Activity: Strong surgeon adoption with multiple Californi
Slide 14: U.S. Quarterly Activity Update
U.S. Quarterly Activity Update Remplir continued to build commercial momentum in the U.S. throughout the September quarter. rsonal use only Sales Education Marketing • 3 new distributors & 2 direct sales • 15 events completed • 17 new surgeons team members signed, widening U.S. 7 cadaver labs, 4 jou
Slide 15: U.S. Remplir commercialisation performance
U.S. Remplir commercialisation performance rsonal use only Distributor coverage tracking ahead of expectations, hospitals and surgeon metrics remain on-track. FY26 Q1 FY27 FY27 Target Comment Cumulative Surgeons1 • Driven by distributor coverage, hospital access and peer-to-peer selling. (total cumu
Slide 16: U.S. Remplir commercial momentum is building
U.S. Remplir commercial momentum is building Hospital approvals and surgeon adoption continue to grow, supported by distributor expansion, medical education and increased product awareness. Unit sales are benefiting from new customers and increased use by established rsonal use only surgeons, with t
Slide 17: Digital marketing supporting commercial growth
Digital marketing supporting commercial growth A scalable digital platform for engaging surgeons and distributors across our markets rsonal use only • New website, distributor portals and practitioner’s hub provide access to the resources required to build confidence in Remplir • Sales teams and dis
Slide 18: American Society for Surgery of the Hand Annual Conference
American Society for Surgery of the Hand Annual Conference rsonal use only >250 new and existing surgeons engaged at the key annual nerve repair conference through hands-on surgical labs, keynote presentations and events, facilitated by leading US nerve surgeons. The sales team now following up in p
Slide 19: Key Takeaways from the Innovation Forum
Key Takeaways from the Innovation Forum rsonal use only “All you have is this thin epineurial-looking layer, which is quite beautiful.” Optimal healing Dr David Brogan (Washington University), describing histology at 17 weeks environment “Seeing this result [clinically], I think is helpful. Especial
Slide 20: Upcoming Catalysts
rsonal use only Upcoming Catalysts
Slide 21: Achievements and upcoming catalysts
Achievements Nerve repair, made SMRT and upcoming rsonal use only 1 Foundations in place for U.S. growth Achieved catalysts Appoint exclusive distributor in UK Achieved First sale in Canada Achieved Appoint THA distributor Achieved First Thailand sale Achieved Initial prostate patient data October P
Slide 22: rsonal use only
@ ortho:cell <x Ya) oO Ajuo asn yeuosie
Slide 23: Authorised for release by the Board
rsonal use only Authorised for release by The Board of Directors of Orthocell Limited P: +61 8 9360 2888 E: paul.anderson@orthocell.com.au orthocell.com